Contents

A strategy focused on healthcare

Delivering strong results

A strong financial structure

Additional information
A strategy focused on healthcare
Group profile

Global technology and services company specializing in healthcare

Global leader in a dynamic environment

Customers

- Pharmaceutical and Life-Sciences companies worldwide
- Doctors, pharmacists and paramedics in Europe & USA
- Healthcare insurance in France

Key figures as of 31/12/2009

- 2009 revenue
  - €874M
  - +4.3%

- Recurring business
  - 65%

- Market capitalization
  - €805M

- Headcount
  - 8,600
2010 Half-year financial snapshot

Revenue:
- HY 2009: €433.9
- HY 2010: €448.8
- Growth: +3.4%

Ordinary EBIT:
- HY 2009: €54.1
- HY 2010: €50.6
- Decrease: -6.4%

Consolidated net earnings group share:
- HY 2009: €17.2
- HY 2010: €19.8
- Increase: +15.2%

Shareholders equity:
- 2009: €466
- 2010: €562
- Increase: +20.2%

Net financial debt:
- HY 2009: €395
- HY 2010: €443
- Increase: +12%

Gearing:
- HY 2009: x0.8
- HY 2010: x0.9
2010 Half-year highlights

Excellent operational performance
- Commercial dynamism
- Services well suited to market demand
- Pertinence of external growth policy

As expected, Q2 2010 increase compensates Q1 2010 decline

<table>
<thead>
<tr>
<th></th>
<th>Q1 2010</th>
<th>Q2 2010</th>
<th>HY 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reported</td>
<td>-1.5%</td>
<td>+8.0%</td>
<td>+3.4%</td>
</tr>
<tr>
<td>L-f-L*</td>
<td>-3.2%</td>
<td>+3.8%</td>
<td>+0.4%</td>
</tr>
</tbody>
</table>

* at constant scope and exchange rate

Ordinary operating income in slight decline
- CRM and strategic data: Q1 revenue delays negatively impact margin
- Healthcare professionals: nice margin improvement
- Insurance and services: fine margin improvement

Successful end of Dendrite integration
- New branding strategy and visual identity for the Group
Snapshot of Cegedim strength

A Rich History
- A 40 years history
- Listed since 1995

A Strong and Stable Shareholder Base
- A majority family shareholder (52%)
- FSI, a strong long term shareholder (15%)
- A regular floating (32%)

A Leading Position
- No direct competitors

A New Visual Identity
- Capitalize on Cegedim brand
- Create a coherent and unified image

A Solid Financial Structure
- Equity reinforced
- A restructured debt
- A strong recurring revenue

A Strong Entry Barriers
- The unique global healthcare professional database
- A very long client relation
- The largest CRM hosting structure
- Global Presence

A Team
- A stable management
- A group of contractors
- A founder president still present

Promising Acquisitions
- SK&A: The best US healthcare professionals database
- Pulse Inc: Take advantage of the coming US market fabulous growth

A Strong Spirit of Innovation
- R&D around 7% of total revenue
- 15% of workforce
Key drivers and 2010 financial outlook

- Continue our organic growth
- Achieve highly targeted acquisitions and complementary for our existing activities
- Increasing our investment in future products
- Ensuring a growth of 2010 revenue between 4% and 5%

Drivers:
- Global market growth
- Emerging countries
- Healthcare system costs
- Dematerialization
- Outsourcing
CRM & STRATEGIC DATA

#1

CLIENTS

**CRM**
- Pharma companies

**Strategic Data**
- Pharma companies
- Government
- University

2009 REVENUE

- **13%**
  - **€116M**

- **56%**
  - **€487M**

HEALTHCARE PROFESSIONALISTS

#2

**CLIENTS**

- Doctors, paramedics
- Pharmacists

2009 REVENUE

- **31%**
  - **€271M**

INSURANCE & SERVICES

#3

**CLIENTS**

- Insurers and health mutuals

2009 REVENUE

- **13%**
  - **€116M**
Cegedim solutions for life science companies

- **UNDERSTAND**
  - Strategic Data
    - Market research
    - Launch assistance
    - Sales force optimization

- **KNOW**
  - OneKey
    - The unique global healthcare professional database
    - More than 6 million healthcare professionals including influential links

- **PERFORM**
  - Mobile Intelligence
    - The only global CRM dedicated to the pharma industry
    - Available on different platforms (PC, iPhone, iPad, Blackberry ...)

- **SUPPORT**
  - SaaS or licence model
    - Global presence
    - Largest hosting facilities in the CRM pharma industry
    - Implementation and training

- **EVALUATE**
  - Reportive, ...
    - Business intelligence, Reporting solutions
    - Effectiveness, ROI, Quality control
    - Governance, Compliance
High commercial dynamism

New offers positive effect
- Mobile Intelligence in SaaS mode, expanding platforms, geographical expansion of new services

Emerging countries fine performance

With the acquisition of SK&A, Cegedim fully takes advantage of the successful strengthening of its OneKey offering in the US

Clear rebound of strategic data activity
Key drivers and strategy

- Global market growth
- Emerging countries
- New markets: Compliance, safety, real life study
- Increasing complexity of therapies
- Outsourcing

- Renewal of existing contracts and new signatures
- Strong growth in emerging markets
- Positive welcome for services model vs. licenses model
- Expand existing offerings geographically and to other healthcare markets
- Enrich the product portfolio
Activities

Physicians
+120,000
- France, UK, Spain, Italy, Belgium and USA
- EMR: Diagnostic, e-prescription, CPOE, Electronic transmission of claims

Pharmacists
16,000
- France & UK
- Complete pharmacy management: sales, stocks, e-transmission

Paramedics
11,000
- France
- Product management software

Presence since July 2010
2010 Half-year highlights

- Fine performance of *Cegedim Healthcare Software*
- French, Spanish and Italian healthcare professionals dynamism
- Wait-and-see attitude of UK physicians

**Acquisition of Pulse Systems, Inc**

- Leading US healthcare software and services supplier
- Give access to the US market for the computerization of healthcare professionals at a very critical time for the Electronic Health Records (EHR) and Practice Management (PM) software markets
  - 17% level of market penetration of EHR in the USA
  - 30 billion dollars of government subventions
  - 70% of total subventions are paid during the first 3 years
- The company is profitable and will likely continue to grow in a rapidly expanding sector
- The company expects to multiply by 4 its revenue within 2014
- Enable to leverage Cegedim complementary activities in North America and transform its European Cegedim Healthcare Software division into a global player by utilizing the Pulse solutions to expand its presence in the US market
Key drivers and strategy

- Set-up of Cegedim Healthcare Software
- Strengthening of synergies at technical level
- Successful development of EPR in Italy and Spain
- Interoperability agreement in UK with EMIS and RIO system
- National Health Information system dedicated to emergency
Insurers and health mutuals

2009 Revenue

31%  €271M
13%  €116M
56%  €487M
Activities

Regroup all products and services for insurers, mutual and contingency companies

IT for healthcare insurers
- Leader in France
- Development in Morocco and Mali

Flows and electronic payment
- Leader in France in the management of direct payment by insurers
2010 Half-year highlights

- Increase of software activity

- Numerous commercial success

- Appropriate offers
  - Activ’Infinite
  - Flow management platforms
  - Relevant business model

- Fine outlooks for 2011

- Cegedim SRH strong commercial dynamism
Key drivers and strategy

Market increasingly attractive and growing competition

Need for differentiation

Need for productivity gains

Need for concentration

Outsourcing

Heavy regulatory burden

- Commercial success
- Rationalization of the products rendering
- Success on international markets
- Online rights servers
Financial results
Well balanced and diversified revenue mix

Good revenue visibility

- Strong recurring revenue model
- Multi-year contracts
- High switching costs
- Strong customer loyalty
Higher year-end seasonal effect

<table>
<thead>
<tr>
<th>Seasonality</th>
<th>2005</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
<th>2009</th>
</tr>
</thead>
<tbody>
<tr>
<td>Turnover</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Q1</td>
<td>23%</td>
<td>23%</td>
<td>18%</td>
<td>22%</td>
<td>24%</td>
</tr>
<tr>
<td>Q2</td>
<td>26%</td>
<td>26%</td>
<td>26%</td>
<td>26%</td>
<td>26%</td>
</tr>
<tr>
<td>Q3</td>
<td>22%</td>
<td>22%</td>
<td>25%</td>
<td>23%</td>
<td>23%</td>
</tr>
<tr>
<td>Q4</td>
<td>29%</td>
<td>29%</td>
<td>30%</td>
<td>28%</td>
<td>28%</td>
</tr>
<tr>
<td>EBIT</td>
<td>48%</td>
<td>48%</td>
<td>44%</td>
<td>45%</td>
<td>48%</td>
</tr>
<tr>
<td></td>
<td>52%</td>
<td>52%</td>
<td>56%</td>
<td>55%</td>
<td>52%</td>
</tr>
</tbody>
</table>

- Traditionally higher sales on software at the end of the year
- Spending of remaining operating budget
- More use of data and market research in Q4 due to reorganization of sale forces, organization of new campaign, annual reporting …
Acquisitions are in line with the Group’s external growth policy presented at the time of the December 2009 capital increase.

We recall that the sole purpose of the bond issue for €300 million on July 27, 2010 is the refinancing of existing bank debt.
A robust half-year

- As expected the Q2 compensated the Q1 decline
- A 4.8% increase in Q2 for CRM and strategic data

By geography
- Europe except France: 26%
- North America: 13%
- Rest of the world: 7%
- France: 55%

By currency
- EUR: 9%
- USD: 12%
- GBP: 13%
- Rest of the world: 66%

* Swiss CRM and Direct Marketing Division of IMS Health
### 2010 Half-year summarized income statement

<table>
<thead>
<tr>
<th></th>
<th>HY 2010</th>
<th>HY 2009</th>
<th>Δ</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>In thousand euros</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Revenue</strong></td>
<td>448,837</td>
<td>433,906</td>
<td>+3.4%</td>
</tr>
<tr>
<td>Capitalized production</td>
<td>15,186</td>
<td>16,616</td>
<td>-8.6%</td>
</tr>
<tr>
<td>Purchased used</td>
<td>-48,637</td>
<td>-47,729</td>
<td>+1.9%</td>
</tr>
<tr>
<td>External expenses</td>
<td>-110,205</td>
<td>-106,409</td>
<td>+3.6%</td>
</tr>
<tr>
<td>Pay roll cost</td>
<td>-213,954</td>
<td>-201,391</td>
<td>+6.2%</td>
</tr>
<tr>
<td>Other operating expenses</td>
<td>-7,109</td>
<td>-6,735</td>
<td>+5.5%</td>
</tr>
<tr>
<td><strong>EBITDA</strong></td>
<td>84,118</td>
<td>88,258</td>
<td>-4.7%</td>
</tr>
<tr>
<td>Depreciation expenses</td>
<td>-33,494</td>
<td>-34,179</td>
<td>-2.0%</td>
</tr>
<tr>
<td><strong>Ordinary operating income</strong></td>
<td>50,624</td>
<td>54,079</td>
<td>-6.4%</td>
</tr>
<tr>
<td>Other income and expenses</td>
<td>-5,448</td>
<td>-4,657</td>
<td>n.s.</td>
</tr>
<tr>
<td><strong>Operating income</strong></td>
<td>45,175</td>
<td>49,422</td>
<td>-8.6%</td>
</tr>
<tr>
<td>Financial result</td>
<td>-21,585</td>
<td>-29,824</td>
<td>-27.6%</td>
</tr>
<tr>
<td>Tax expense</td>
<td>4,065</td>
<td>2,726</td>
<td>+49.1%</td>
</tr>
<tr>
<td>Share of net earnings of equity method companies</td>
<td>396</td>
<td>368</td>
<td>+7.6%</td>
</tr>
<tr>
<td><strong>Consolidated net earnings</strong></td>
<td>19,921</td>
<td>17,240</td>
<td>+15.6%</td>
</tr>
<tr>
<td>Minority interests</td>
<td>72</td>
<td>3</td>
<td>n.s.</td>
</tr>
<tr>
<td><strong>Group share</strong></td>
<td>19,849</td>
<td>17,237</td>
<td>+15.2%</td>
</tr>
</tbody>
</table>
# 2010 Half-year Group margin evolution

<table>
<thead>
<tr>
<th>Group margin</th>
<th>HY 2010</th>
<th>HY 2009</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>in K€</td>
<td>in %</td>
</tr>
<tr>
<td>Revenue</td>
<td>448,837</td>
<td>433,906</td>
</tr>
<tr>
<td>EBITDA</td>
<td>84,118</td>
<td>88,258</td>
</tr>
<tr>
<td>Ordinary operating profit</td>
<td>50,624</td>
<td>54,079</td>
</tr>
<tr>
<td>Other income and expenses from</td>
<td>-5,448</td>
<td>-4,657</td>
</tr>
<tr>
<td>operations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operating profit</td>
<td>45,175</td>
<td>49,422</td>
</tr>
<tr>
<td></td>
<td>10.1%</td>
<td>11.4%</td>
</tr>
</tbody>
</table>
### 2010 Half-year financial result evolution

<table>
<thead>
<tr>
<th>In thousand euros</th>
<th>HY 2010</th>
<th>HY 2009</th>
<th>Δ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost of financial debt</td>
<td>-12,283</td>
<td>-20,304</td>
<td>-39.5%</td>
</tr>
<tr>
<td>Ineffective hedging</td>
<td>- 2,992</td>
<td>-3,957</td>
<td>-24.4%</td>
</tr>
<tr>
<td>Exchange difference</td>
<td>-6,863</td>
<td>-6,587</td>
<td>+4.2%</td>
</tr>
<tr>
<td>Income or cash equivalent</td>
<td>564</td>
<td>829</td>
<td>-32.0%</td>
</tr>
<tr>
<td>Other</td>
<td>-11</td>
<td>195</td>
<td>-105.6%</td>
</tr>
<tr>
<td><strong>Financial result</strong></td>
<td><strong>-21,585</strong></td>
<td><strong>-29,824</strong></td>
<td><strong>-27.6%</strong></td>
</tr>
<tr>
<td>Income taxes</td>
<td>-16,134</td>
<td>-3,005</td>
<td></td>
</tr>
<tr>
<td>Deferred income taxes</td>
<td>12,069</td>
<td>279</td>
<td></td>
</tr>
<tr>
<td><strong>Tax expense</strong></td>
<td><strong>-4,065</strong></td>
<td><strong>-2,726</strong></td>
<td></td>
</tr>
</tbody>
</table>
CRM and strategic data

Margin

<table>
<thead>
<tr>
<th></th>
<th>HY 2010</th>
<th>HY 2009</th>
<th>Δ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>249.1</td>
<td>240.8</td>
<td>+3.5%</td>
</tr>
<tr>
<td>Q1</td>
<td>111.5</td>
<td>117.5</td>
<td>-5.1%</td>
</tr>
<tr>
<td>Q2</td>
<td>137.6</td>
<td>123.2</td>
<td>+11.6%</td>
</tr>
<tr>
<td>Ordinary operating profit</td>
<td>18.3</td>
<td>24.3</td>
<td>-6.0%</td>
</tr>
<tr>
<td>Margin</td>
<td>7.3%</td>
<td>10.1%</td>
<td></td>
</tr>
</tbody>
</table>

Revenue breakdown

- France: 33%
- Europe ex. France: 31%
- North America: 24%
- Rest of the world: 12%

Comments

- Revenue Q2 2010 increase compensates Q1 2010 decline

- **CRM**
  - Strong commercial dynamism
  - Emerging countries fine performance
  - Delays in executing certain large-scale projects
  - Increase of payroll costs

- **Strategic data**
  - Clear rebound in its revenues and profitability in Q2
Healthcare professionals

**Margin**

<table>
<thead>
<tr>
<th>In million Euros</th>
<th>HY 2010</th>
<th>HY 2009</th>
<th>Δ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>138.7</td>
<td>137.7</td>
<td>+0.8%</td>
</tr>
<tr>
<td>Q1</td>
<td>64.5</td>
<td>65.3</td>
<td>-1.2%</td>
</tr>
<tr>
<td>Q2</td>
<td>74.3</td>
<td>72.4</td>
<td>+2.6%</td>
</tr>
<tr>
<td>Ordinary operating profit</td>
<td>23.8</td>
<td>22.9</td>
<td>€+1.0</td>
</tr>
<tr>
<td>Margin</td>
<td>17.2%</td>
<td>16.6%</td>
<td></td>
</tr>
</tbody>
</table>

**Revenue breakdown**

- France: 77%
- Europe ex. France: 23%

**Comments**

- Revenue Q2 2010 increase compensates Q1 2010 decline
- Ordinary operation margin increase of 60 bp
- Increase of margin despite
  - Negative impact of the wait-and-see attitude of UK physicians
  - Cegelease negative impact
- Acquisition of Pulse Systems Inc in the USA in July 2010
Insurance and services

**Margin**

<table>
<thead>
<tr>
<th>In million euros</th>
<th>HY 2010</th>
<th>HY 2009</th>
<th>Δ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>61.0</td>
<td>55.5</td>
<td>+9.9%</td>
</tr>
<tr>
<td>Q1</td>
<td>29.6</td>
<td>25.9</td>
<td>+14.4%</td>
</tr>
<tr>
<td>Q2</td>
<td>31.4</td>
<td>29.6</td>
<td>+5.9%</td>
</tr>
<tr>
<td>Ordinary operating profit</td>
<td>8.5</td>
<td>6.9</td>
<td>Me +1.6</td>
</tr>
<tr>
<td>Margin</td>
<td>14.0%</td>
<td>12.5%</td>
<td></td>
</tr>
</tbody>
</table>

**Revenue breakdown**

- 1%: France
- 99%: Rest of the world

**Comments**

- Robust trend of revenue organic growth in Q1 and Q2
- 23% increase of ordinary operating margin
- 150 bp increase of ordinary operating margin
- Fine outlooks for 2011
A strong financial structure
A cash flow generating model

Operating cash flow before net financial debt expense and taxes

%  Marge cash flow
2010 Half-year consolidated cash flow (EUR millions)

- Operating cash flow before net financial debt expense and taxes: 77.0
- Financial interest paid: 9.4
- Change in cash: 19.4
- Change in working capital: 17.8
- Investements: 54.7
- Net loan repaid: 57.6
- Other financial income and expenses paid or received: 8.1
- Capex: 23.8
- Cegelease: 5.2
- Net acquisitions: 25.7

- Working capital seasonal effect
- Cash flow after net cost of financial debt and taxes similar to June 30, 2009
**Successful M€ 300 bond issue**

**Characteristics**
- Rating: BB+
- Amount: M€ 300
- Maturity date: July 27, 2015
- Annual coupon: 7.000% fixed rate
- 70% of the demand were located outside of France

**Objectives**
- Maturity extension
  - Almost 80% of total debt has more than 3 year maturity
- Diversifying source of financing

**Use**
- 100% of the bond issue will be used to reimburse part of the existing bank debt
Significant improvement in the debt structure

Debt structure by as of June 30, 2010

<table>
<thead>
<tr>
<th>Type</th>
<th>Currency</th>
<th>Hedging</th>
<th>Maturity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Term</td>
<td>M€262</td>
<td>67%</td>
<td>16% &lt; 1 year</td>
</tr>
<tr>
<td></td>
<td>M$149</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revolver</td>
<td>M$72.5</td>
<td>33%</td>
<td>84% &gt; 1 year</td>
</tr>
<tr>
<td></td>
<td>M$50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subordinated</td>
<td>M€45</td>
<td>33%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>USD</td>
<td>Floating rate</td>
<td></td>
</tr>
</tbody>
</table>

Indicative new debt structure

<table>
<thead>
<tr>
<th>Type</th>
<th>Currency</th>
<th>Hedging</th>
<th>Maturity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bond</td>
<td>M€300</td>
<td>86%</td>
<td>30% &lt; 3 years</td>
</tr>
<tr>
<td>Term</td>
<td>M€139</td>
<td>86%</td>
<td></td>
</tr>
<tr>
<td>Revolver</td>
<td>M€99</td>
<td>14%</td>
<td>70% &gt; 3 years</td>
</tr>
<tr>
<td>Subordinated</td>
<td>M€45</td>
<td>14%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>USD</td>
<td>Floating</td>
<td></td>
</tr>
</tbody>
</table>

Net bank debt repayment as of June 30, 2010

<table>
<thead>
<tr>
<th>Year</th>
<th>Term</th>
<th>Drawn RCF</th>
<th>Undrawn RCF</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>M€86</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>M€86</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td>M€86</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>M€64</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Indicative new net bank debt repayment

<table>
<thead>
<tr>
<th>Year</th>
<th>Term</th>
<th>Drawn RCF</th>
<th>Undrawn RCF</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>M€49</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>M€49</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td>M€49</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>M€61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>M€43</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>M€300</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Additional information
Half-year average daily volume

Adjusted stock price (au 07/30/2010)

Share ID
- Quotation: NYSE Euronext Paris - compartiment B
- IPO date: Avril 1995
- ISIN Code: FR0000053506
- Code: CGDM.PA (Reuters), CGM (Bloomberg)
- Closing Date: December 31st
- Valeur de l’action à l’introduction: 9.52 euros
- Number of shares as of 06/30/2010: 13 997 173
- Market capitalisation as of 06/30/2010: 784 millions d’euros

Analysts coverage
- CA Cheuvreux: Michaël Beucher
- CM-CIC Securities: Jean-Pascal Brivady
- Gilbert Dupont: Nicolas Montel / Guillaume Cuvillier
- Natixis Securities: Thomas Le Quang
- Oddo & Cie: Xavier-Emmanuel Pingault
- Société Générale: Patrick Jousseau
2010 finance agenda

**January 8**
Shareholders’ general meeting

**February 11**
2009 revenue

**April 13**
2009 Annual results

**April 14**
SFAF Meeting

**May 6**
2010 Q1 revenue

**August 5**
2010 Q2 revenue

**September 23**
2010 Half-year results

**September 24**
SFAF Meeting

**November 15**
2010 Q3 revenue
We welcome your questions and comments

Jan Eryk UMIASTOWSKI
Chief Investment offices
Chief Investor Relation
Tel: +33 (0)1 49 09 33 36
investor.relations@cegedim.com
www.cegedim.fr/finance
Strong and stable shareholder base

Board of directors

- Jean-Claude Labrune ........................................ Chairman of the board
- Laurent Labrune
- Aude Labrune
- Jean-Louis Mery
- Pierre Marucchi ................................................ FCB representative
- Jacques-Henri David ......................................... Appointed by FSI
- Nicolas Manardo ................................................ Appointed by FSI
- Philippe Alaterre .............................................. GERS representative
- Anthony Roberts ................................................ Alliance Healthcare France representative
- Jean-Pierre Cassan ............................................. Independent director in the sense of the AFEP-MEDEF corporate governance code

- Extended to 10 directors on January 2010
Where we come from

Jean-Claude Labrune founds Cegedim

1969

Launch of CRM activities in France

1979

Computerization of doctors in France

International expansion begins

Launch of the first platform of electronic data exchange

1984

Computerization of health insurance and mutual companies

1990

Establishment in United States

1991

Acquisition of Dendrite International

1995

Acquisition in US of SK&A and Pulse

1999

Bond issue of M€300

2000

The FSI* acquires a 15% stake of Cegedim €180 million rights issue

2001

Cegedim exceeds €500 million

2008

Alliance Healthcare France acquires a 10% stake of Cegedim

2008

2007

2010

IPO on Paris stock exchange
No direct competitors on the entire value chain